NovoCure LimitedNVCRNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-3.23%
↓ 165% below average
Average (39q)
4.94%
Historical baseline
Range
High:35.14%
Low:-25.82%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -3.23% |
| Q2 2025 | 3.82% |
| Q1 2025 | 5.01% |
| Q4 2024 | -1.30% |
| Q3 2024 | -5.59% |
| Q2 2024 | 6.51% |
| Q1 2024 | -4.99% |
| Q4 2023 | 1.28% |
| Q3 2023 | -3.25% |
| Q2 2023 | -7.16% |
| Q1 2023 | 8.91% |
| Q4 2022 | 5.51% |
| Q3 2022 | -8.97% |
| Q2 2022 | 35.14% |
| Q1 2022 | -25.82% |
| Q4 2021 | 18.26% |
| Q3 2021 | -4.32% |
| Q2 2021 | 9.58% |
| Q1 2021 | 4.35% |
| Q4 2020 | 34.08% |
| Q3 2020 | 9.69% |
| Q2 2020 | 18.39% |
| Q1 2020 | 6.44% |
| Q4 2019 | 26.51% |
| Q3 2019 | -3.54% |
| Q2 2019 | 14.15% |
| Q1 2019 | 13.36% |
| Q4 2018 | 14.99% |
| Q3 2018 | 15.07% |
| Q2 2018 | 2.32% |
| Q1 2018 | 10.51% |
| Q4 2017 | 8.36% |
| Q3 2017 | -1.05% |
| Q2 2017 | -0.43% |
| Q1 2017 | 11.10% |
| Q4 2016 | -17.22% |
| Q3 2016 | -9.59% |
| Q2 2016 | -1.11% |
| Q1 2016 | 5.53% |
| Q4 2015 | 6.21% |